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Hidradenitis suppurativa (HS) is a chronic inflammatory dermatosis that presents with nodules, cysts, 
abscesses and sinus tracts in apocrine gland-bearing areas. It is thought to occur secondary to 
follicular occlusion, has been associated with smoking and obesity and may be inherited in an 
autosomal dominant manner in a minority of cases1. Heterozygous mutations in the gamma-
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secretase genes PSENEN, PSEN1 and NCSTN  underlie 0-7% of cases2,3.  Gamma-secretase is an intra-
membranous protease complex comprised of NCSTN, Presenilin, PEN-2 and APH1 involved in 
regulated intra-membrane proteolysis and the subsequent clearance of substrates from cell 
membranes (endopeptidase and carboxypeptidase activity). The functional effects of gamma-
secretase gene mutations in HS are yet to be elicited. It was hypothesised that two previously 
reported mutations (NCSTN c.1125+1 G>A, PSENEN c.66_67insG)3 would affect corresponding RNA 
and protein expression/ function and affect gamma-secretase enzyme activity.  
 
This study was approved by the London Stanmore Research Ethics Committee (11/LO/0966) and 
conducted in accordance with Declaration of Helsinki principles. Diagnostic criteria are detailed in 
the supplementary methods. Two 6mm axillary skin biopsies (affected and unaffected skin) were 
taken from two mutation-positive individuals and three healthy volunteers for 
immunohistochemistry and cell culture. DNA, RNA and protein was extracted from primary human 
fibroblasts and analysed via agarose electrophoresis, Sanger sequencing, gene expression assays and 
immunoblotting . Gamma-secretase enzyme activity assays were performed using a well established 
in vitro enzyme activity assay (supplementary methods)4. Statistical analyses were performed as 
detailed in supplementary methods. 
 
NCSTN and PSENEN co-localised to the hair follicle, sebaceous gland, apocrine gland, epidermis and 
inflammatory infiltrates in healthy and mutation-positive human skin (Figs 1, S1, S2). There was no 
difference in NCSTN or PEN-2 epidermal staining intensity in mutation-positive versus healthy 
volunteer skin. Antibody specificity was verified using grade IV invasive breast cancer tissue (NCSTN 
expression is upregulated in invasive ductal breast cancer 5) and by showing co-localisation of NCSTN 
and PEN-2 in healthy skin (replicated using a second NCSTN antibody, Fig. S3). 
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Agarose electrophoresis and sequencing of the full length NCSTN transcript revealed that NCSTN 
exon 9 is missing in the NCSTN c.1125+1G>A mutant allele (Fig. S4). NCSTN transcript expression was 
significantly reduced in mutant versus control primary human fibroblasts (Fig. S5A, S5B). An 
incremental increase in transcript abundance was observed in cycloheximide treated cells over a 24 
hour period (Fig. S5C), suggesting that the mutant transcript is subject to decay. Immunoblotting 
revealed a significant corresponding reduction in mature nicastrin expression in mutant versus 
control fibroblasts (p<0.001, Fig. S6), with no additional protein bands to support the presence of a 
mutant protein (specificity of band validated by siRNA knockdown, Fig. S7).  
 
Amplification and direct sequencing of the PSENEN transcript from PSENEN mutant fibroblasts 
revealed the c.66_67insG insertion (Fig. S8). This is predicted to alter the reading frame and result in 
an altered and elongated PEN-2 protein product (p.Phe23ValfsX98, Fig. S9). Transcript and 
corresponding PEN-2 protein expression was significantly reduced in mutant versus control 
fibroblasts (p<0.001, Figs. S10, S11). No additional protein bands were identified to support the 
presence of a mutant protein.  
 
Gamma-secretase enzyme activity assays revealed no difference in the total number of mature 
gamma-secretase complexes present (assessed by measuring PSEN1-CTF), complex maturity (as 
measured by the PSEN1-CTF/ PEN-2 ratio), endopeptidase enzyme activity per complex (as 
measured by the AICD-Flag/ PSEN1-CTF ratio) or carboxypeptidase activity (as measured by the 
Aβ42:Aβ40 ratio) in NCSTN and PSENEN mutant fibroblasts versus controls (Fig 2). S20 cells (over-
express gamma-secretase components) acted as a positive control and the gamma-secretase 
inhibitor L458 acted as a negative control (Fig S12)6. NCSTN and PEN-2 blot densities were calculated 
from solubilised membrane preparations generated for the enzyme activity assays. In contrast to 
total cell fractions, there was no significant difference in NCSTN and PEN-2 expression in solubilised 
membrane fractions harvested from mutant versus control fibroblasts (Fig. S13, Fig. S14).  
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These data demonstrate that the gamma-secretase components NCSTN and PEN-2 are expressed in 
cutaneous structures that are commonly distorted or altered in HS7,8. The two mutations studied 
share a downstream pathogenic mechanism of haploinsufficiency (consistent with other globally 
reported gamma-secretase gene mutations reportedly reducing transcript abundance 9-11). The 
subsequent total cell reduction in respective protein expression was not, however, replicated in cell 
membrane preparations. Gamma-secretase protein expression is very tightly regulated 12, less than 
5% of assembled complexes reach the cell membrane. 50% wild type protein may therefore be 
sufficient to support complex assembly and function. Notch 1, 2 and 3 knockdown in mice results in 
follicular keratinisation 13, potentially implicating gamma-secretase-Notch signalling in HS. However, 
only one of four missense mutations so far reported in HS was found to affect Notch processing 14, 
and that effect was negated with heterozygous expression of the mutant allele, again supporting the 
notion that 50% wild-type protein can maintain enzyme function. It may therefore be postulated 
that heterozygous mutations in the gamma-secretase genes are not sufficient to cause HS alone. It 
may be that partial reductions in protein expression only become functionally detrimental in 
situations of cellular stress. The unusual and characteristic cutaneous distribution of HS might 
implicate intrinsic and extrinsic factors such as temperature, sweat, friction, glandular secretion and 
microbes in disease pathogenesis. Temperature, pH and salt concentrations have all been shown to 
affect endopeptidase and carboxypeptidase enzyme activity in vitro6 and these factors require 
further investigation in this context. 
 
Limitations in this study include the in vitro nature of the experiments, the efficiency of protein 
solubilisation and the accuracy with which one can measure the concentration of solubilised cell 
membrane protein when working with protein complexes. The immunohistochemistry data would 
imply that keratinocytes may be a relevant cell type around which to focus future study.  
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The nature of the globally reported gamma-secretase gene mutations in HS, these data 
demonstrating haploinsufficiency, and in vivo data showing that NCSTN or PSEN1 knockdown results 
in the development of follicular keratinisation, follicular atrophy and the formation of epidermal 
cysts 13,15,16, suggest that a reduction in respective gene product may be involved in the pathogenesis 
of some cases of HS. Ongoing efforts to elicit the functional consequences of these mutations on 
gamma-secretase activity and downstream signalling pathways have the potential to identify novel 
therapeutic targets in this debilitating condition.  
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FIGURE LEGENDS 
Figure 1. NCSTN and PEN-2 expression in healthy volunteer axillary skin. NCSTN and PEN-2 staining 
co-localised in the epidermis, hair follicle, sebaceous gland and apocrine glands. This represents skin 
harvested from one healthy volunteer, but the distribution of staining was the same in all 
individuals. Scale bar = 50µm.  
Figure 2. Gamma-secretase enzyme activity assay results. A) PSEN1-CTF expression in solubilised 
membrane preparations harvested from mutant and control fibroblasts.  There was no significant 
difference in PSEN1-CTF expression in the NCSTN or PSENEN mutant fibroblasts versus controls 
(error bars = standard error (SE)). B) PSEN1 CTF/ PEN-2 ratio for each sample expressed as a 
percentage of the ratio observed in the positive control S20 cells (representative of gamma-
secretase complex maturity). There was no discernible difference in mutant fibroblasts versus 
control subjects (error bars = SE). C) Gamma-secretase enzyme activity per complex expressed as a 
percentage of the positive control (S20 cell line).  There was no significant difference in enzyme 
activity per complex between mutant fibroblasts and controls (error bars = SE). D) Aβ42: Aβ40 ratios 
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expressed as a percentage of the ratio derived from S20 cells.  There was no significant difference in 
the ratio derived in assays run with samples harvested from mutant fibroblasts versus control 
fibroblasts (error bars = SE). 
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